By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Biotech Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 888-227-5624 Fax: n/a


Company News
MorphoSys AG Sues Janssen Biotech Inc. (JNJ) And Genmab A/S (GEN.CO) For Patent Infringement 4/4/2016 11:46:30 AM
X-Chem Announces License With Janssen Biotech Inc. (JNJ) For Protein:Protein Inhibitor Program In Inflammatory Disease 3/30/2016 10:54:15 AM
Janssen Biotech Inc. (JNJ) Release: U.S. FDA Approves IMBRUVICA (ibrutinib) For First-Line Treatment Of Chronic Lymphocytic Leukemia 3/7/2016 6:21:17 AM
Scholar Rock Announces Option Exercised By Janssen Biotech Inc. (JNJ) In Immuno-Oncology Collaboration Focused On Supracellular Activation 1/7/2016 11:15:25 AM
Janssen Biotech Inc. (JNJ) Release: IMBRUVICA (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity And Promising Survival Outcomes In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia With Del 17p 12/8/2015 8:48:57 AM
Janssen Biotech Inc. (JNJ) Release: IMBRUVICA (Ibrutinib) Phase 3 RAY Data Show Significant Improvements In Progression-Free Survival Versus Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma 12/7/2015 7:29:29 AM
Janssen Biotech Inc. (JNJ) Submits Applications Seeking Approval Of STELARA In United States And European Union For Crohn's Disease 11/30/2015 6:51:21 AM
Janssen Biotech Inc. (JNJ) Release: Additional Efficacy And Safety Data For IMBRUVICA (Ibrutinib) Submitted To FDA 11/13/2015 7:26:53 AM
Janssen Biotech Inc. (JNJ) Launches New Platform Focused On Improving Disease Monitoring For People Living With Inflammatory Bowel Diseases (IBD) 11/12/2015 8:51:06 AM
Janssen Biotech Inc. (JNJ) Data Presentations At American College of Rheumatology Meeting Showcase Commitment To Rheumatologic Diseases 11/4/2015 7:25:51 AM